# Ascending Multiple-Dose Study to Evaluate VIA-3196 in Healthy Subjects

> **NCT01519531** · PHASE1 · COMPLETED · sponsor: **Madrigal Pharmaceuticals, Inc.** · enrollment: 48 (actual)

## Conditions studied

- Drug Safety

## Interventions

- **DRUG:** Placebo
- **DRUG:** VIA-3196

## Key facts

- **NCT ID:** NCT01519531
- **Lead sponsor:** Madrigal Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-01
- **Primary completion:** 2012-11
- **Final completion:** 2012-11
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2012-12-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01519531

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01519531, "Ascending Multiple-Dose Study to Evaluate VIA-3196 in Healthy Subjects". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT01519531. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*